Get the latest news, insights, and market updates on PSTV (Plus Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced it has completed a Type B meeting with the U.S. Food and Drug Administration (FDA) on November 7th to discuss its REYOBIQ clinical development plans for leptomeningeal metastases (LM) including the design of a planned pivotal or registrational trial. Nov 24, 2025 - $PSTV
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: HUM), effective October 29, 2025, covering approximately 16 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total pol Nov 20, 2025 - $PSTV
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
No near-term Reverse Stock Split required to meet Bid Price RuleHOUSTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces it has received an additional 180-day extension period from the Nasdaq Listing Qualifications Department (the “Nasdaq Staff”) to regain compliance with the Nov 17, 2025 - $PSTV
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ™ and ReSPECT-LM, and future directions and needsHOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, Melano Nov 6, 2025 - $PSTV
How Recent Developments Are Rewriting the Plus Therapeutics Investment Story
Plus Therapeutics stock has recently seen its fair value estimate increase from $7.88 to $9.67, following an update to the company’s financial outlook. This shift comes as analysts recognize improvements in revenue growth projections and factor in a slight uptick in the discount rate, which reflects both opportunity and ongoing risks. Stay tuned to discover how you can keep track of these evolving assessments and stay informed on the latest developments in Plus Therapeutics’ market... Nov 4, 2025 - $PSTV
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the third quart Oct 30, 2025 - $PSTV
Plus: Q3 Earnings Snapshot
HOUSTON (AP) — Plus Therapeutics, Inc. PSTV) on Thursday reported a loss of $4.4 million in its third quarter. On a per-share basis, the Houston-based company said it had a loss of 4 cents. Oct 30, 2025 - $PSTV
United Therapeutics (UTHR) Beats Q3 Earnings Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of +3.92% and -2.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Oct 29, 2025 - $PSTV
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subs Oct 21, 2025 - $PSTV
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple